Intelligence · Clinical Pipeline
George Institute for Pipeline
All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.
- Programs
- 42
Quick answer
George Institute for has 42 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.
The George Institute
AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.
1 trial -
A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation
The George Institute
Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation
1 trial -
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
The George Institute
Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
1 trial -
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
The George Institute
Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
1 trial -
A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)
The George Institute
Crimean Congo Hemorrhagic Fever
1 trial -
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia
The George Institute
Relapse/ refractory acute Leukemia
1 trial -
A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.
The George Institute
Prevention of Cholera disease
1 trial -
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment
The George Institute
Newly diagnosed and/or previously treated IDH1-mutated malignancies
1 trial -
A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.
The George Institute
Alzheimer´s disease
1 trial -
A randomised, assessor-blinded, controlled, healthy volunteer, Phase I study to assess skin irritation and sensitization potential of a novel 5% lidocaine medicated plaster
The George Institute
None. Healthy subjects
1 trial -
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer
The George Institute
Refractory metastatic Her2 positive breast cancer
1 trial -
A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT
The George Institute
Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors
1 trial -
A study to find out how healthy people tolerate a new drug called S221237.
The George Institute
Parkinson disease (PD)
1 trial -
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
The George Institute
Neoadjuvant therapy in locally-advanced rectal cancer
1 trial -
Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients
The George Institute
Kidney trasplants
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condition.
1 trial -
CAR123 T cell treatment of relapsed/refractory hematologic malignancies.
The George Institute
Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.
1 trial -
CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
The George Institute
Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma
1 trial -
CD5CAR-NK cells for refractory invasive mold disease
The George Institute
refractory invasive mold disease
1 trial -
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
The George Institute
Acute leukemia and myelodysplastic syndromes
1 trial -
CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions
The George Institute
No medical condition
1 trial -
Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (High Fat High Calorie Meal and Standard Meal).
The George Institute
No medical condicion.
1 trial -
First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers
The George Institute
Lynch Syndrome
1 trial -
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma
The George Institute
Relapsed/refractory B-cell aggressive lymphoma
1 trial -
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.
The George Institute
No medical condition.
1 trial -
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condicion.
1 trial -
NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma
The George Institute
resectable esophagogastric adenocarcinoma
1 trial -
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
The George Institute
Non-small cell lung cancer (NSCLC)
1 trial -
Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol
The George Institute
Pneumonia
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
The George Institute
Diabetic retinopathy.
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
The George Institute
Diabetic retinopathy.
1 trial -
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.
The George Institute
graft-versus-host disease
1 trial -
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.
The George Institute
graft-versus-host disease
1 trial -
Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.
The George Institute
No medical condition.
1 trial -
Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.
The George Institute
Idiopathic Pulmonary Fibrosis
1 trial -
Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).
The George Institute
advanced or metastasic triple-negative breast cancer
1 trial -
clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee
The George Institute
Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments
1 trial -
„INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial
Frequently asked questions
How many pipeline programs does George Institute for have?
42 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs